Drug Trial Radar · NCT00960141
A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED)
Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
829
Actual
Start
Aug 2000
Primary completion
Oct 2000
Study completion Nov 2000
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of the ability of montelukast to improve signs and symptoms of seasonal allergic rhinitis compared with placebo. Loratadine is included in the study as an active control.
Conditions
- Seasonal Allergic Rhinitis
Interventions
montelukast sodiumDrug
montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
Comparator: loratadineDrug
loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
Comparator: placeboDrug
placebo tablet, taken orally once daily at bed time for 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Daytime Nasal Symptoms ScoreTime frame: Baseline and Week 2
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.